Company Analysis
Sign in

Innoviva, Inc. (INVA)

Nasdaq: INVA · Pharmaceutical Preparations · Burlingame, CA · filing with the SEC since 2000
Full chart Alerts Compare
Grade6.2
◀ Past 6.4● Present 6.5▶ Future 5.7
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

421 patents granted to the 8 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Innoviva, Inc.’s names, not what it holds today.

Patents granted
421
421 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 2 in 2023
Applications published
267
2 of them in 2025
Names they are printed under
8
a former name, a subsidiary
By yearGrantedApplications published
'10'11'12'13'14'15'16'17'18'19'20'21'22'23'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name8 counted
Theravance, Inc. a former name
US, as the owner printed on each patent
387 granted
214 published
Tetraphase Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
17 granted
5 published
La Jolla Pharmaceutical Company a subsidiary
named as the applicant on its applications, in US
0 granted
20 published
Tetraphase Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
19 published
Advanced Medicine, Inc. a former name
US, as the owner printed on each patent
13 granted
1 published
La Jolla Pharma, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
La Jolla Pharma, LLC a subsidiary
US, as the owner printed on each patent
3 granted
0 published
Advanced Medicine East, Inc. a subsidiary
US, as the owner printed on each patent
1 granted
0 published
Names not counted (2)
Entasis Therapeutics Inc.
Most of its patents print GB; this name counts in US. 0 granted and 13 published under it are not counted.
Entasis Therapeutics Inc.
Most of its patents print GB; this name counts in US. 11 granted and 2 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 8, 202512,269,807Crystalline forms of eravacyclinePharmaceuticalsTetraphase Pharmaceuticals, Inc.
Feb 21, 202311,583,568Methods for administering angiotensin IIPharmaceuticalsLa Jolla Pharma, LLC
Feb 14, 202311,578,044Crystalline forms of eravacyclinePharmaceuticalsTetraphase Pharmaceuticals, Inc.
Jan 11, 202211,219,662Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin IIPharmaceuticalsLa Jolla Pharma, LLC
Mar 30, 202110,961,190Crystalline forms of eravacyclinePharmaceuticalsTetraphase Pharmaceuticals, Inc.
Feb 9, 202110,913,712Tetracycline compoundsPharmaceuticalsTetraphase Pharmaceuticals, Inc.
Apr 14, 202010,618,879Semi-synthesis proceduresOrganic fine chemistryTetraphase Pharmaceuticals, Inc.
Sep 10, 201910,406,201Methods for administering angiotensin IIPharmaceuticalsLa Jolla Pharma, LLC
Jun 11, 201910,315,992Tetracyline compoundsPharmaceuticalsTetraphase Pharmaceuticals, Inc.
Oct 2, 201810,087,157Semi-synthesis proceduresOrganic fine chemistryTetraphase Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Mar 20, 20252025/0090622ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETOPharmaceuticalsLa Jolla Pharma, LLC
Feb 6, 20252025/0042843C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDSOrganic fine chemistryTetraphase Pharmaceuticals, Inc.
Dec 28, 20232023/0416212CRYSTALLINE FORMS OF ERAVACYCLINEPharmaceuticalsTetraphase Pharmaceuticals, Inc. · patent 12,269,807 granted from it
Apr 20, 20232023/0122651C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDSOrganic fine chemistryTetraphase Pharmaceuticals, Inc.
Sep 1, 20222022/0273757METHODS FOR ADMINISTERING ANGIOTENSIN II BY MONITORING RENIN LEVELSPharmaceuticalsLa Jolla Pharma, LLC
Jun 23, 20222022/0193183COMPOSITIONS AND METHODS FOR TREATING RENAL FAILUREPharmaceuticalsLa Jolla Pharmaceutical Company
May 26, 20222022/0160816ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETOPharmaceuticalsLa Jolla Pharma, LLC
Dec 23, 20212021/0395198POLYMORPHIC FORMS OF A COMPOUND AND USES THEREOFOrganic fine chemistryTetraphase Pharmaceuticals, Inc.
Nov 25, 20212021/0363103CRYSTALLINE FORMS OF ERAVACYCLINEPharmaceuticalsTetraphase Pharmaceuticals, Inc. · patent 11,578,044 granted from it
Jun 24, 20212021/0187058METHODS FOR ADMINISTERING ANGIOTENSIN IIPharmaceuticalsLa Jolla Pharma, LLC · patent 11,219,662 granted from it
What it applied for, 2024 to 2025: Organic fine chemistry 1 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton INVA · research, not advice